Company Description
Biogen IDEC Inc.. The Group's principal activity is the research, development, manufacture and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. The Group's two commercial products, Rituxan ...
Related Business Topics
Breaking News
Reuters India - November 25, 2009 3:35 PM
BOSTON (Reuters) - Rituxan, a drug used to treat cancer and rheumatoid arthritis, may help slow the development of newly discovered type 1 or juvenile diabetes, researchers reported on Wednesday. The drug may interfere with the body's mistaken ...
Reuters - November 25, 2009 3:11 PM
By Gene Emery BOSTON (Reuters) - Rituxan, a drug used to treat cancer and rheumatoid arthritis, may help slow the development of newly discovered type 1 or juvenile diabetes, researchers reported on Wednesday. The drug may interfere with the body's ...
Reuters UK - November 25, 2009 2:47 PM
* Rituxan stops immune cells that destroy healthy tissue * Single dose slowed development of diabetes * Multiple doses may be required BOSTON, Nov 25 (Reuters) - Rituxan, a drug used to treat cancer and rheumatoid arthritis, may help slow the development ...
Reuters - November 24, 2009 2:03 PM
CAMBRIDGE, Mass.--(Business Wire)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, ...
Reuters - November 23, 2009 5:45 AM
Experienced Drug Hunters Armed with Structure-Based G Protein-Coupled Receptor (GPCR) Drug Discovery Technology From The Scripps Research Institute SAN DIEGO--(Business Wire)-- Receptos, Inc., a privately held biopharmaceutical company, announced the ...
